Claims
- 1. A composition comprising particles of bioactive glass with a particle size less than about 20 μm in diameter and a suitable carrier for oral, intramuscular, intraperitoneal or intravenous administration.
- 2. The composition of claim 1, wherein the carrier is suitable for intravenous administration.
- 3. The composition of claim 1, wherein the carrier is suitable for intramuscular or intraperitoneal administration.
- 4. The composition of claim 1, additionally comprising one or more therapeutic agents.
- 5. The composition of claim 4, wherein one or more therapeutic agents are selected from the group consisting of healing promotion agents, growth factors, anti-inflammatory agents, and anesthetics.
- 6. The composition of claim 1 wherein the glass includes between about 40 and 86 percent by weight of SiO2, between about 0 and 30 percent by weight of Na2O, between about 4 and 46 percent by weight of CaO and between about 1 and 15 percent by weight of P2O5.
- 7. The composition of claim 1, wherein the bioactive glass has a particle size range less than about 2 microns.
- 8. A method for systemically increasing IL-6 levels in a patient, comprising administering to the patient an effective, IL-6 increasing amount of bioactive glass particles with a size less than about 20 μm.
- 9. A composition comprising particles of a material with a particle size less than about 20 μm which biodegrades, produces elevated serum concentrations of calcium and phosphorous ions, does not cause elevated plasma TNF-αconcentrations, and does cause elevated plasma IL-6 concentrations, in combination with a suitable carrier for oral, intramuscular, intraperitoneal or intravenous administration.
- 10. A method for increasing IL-6 levels in a patient, comprising administering to the patient an effective, IL-6 increasing amount of bioactive glass particles with a size less than about 20 μm.
- 11. The method of claim 10 wherein the bioactive glass particles are administered locally.
- 12. A method for increasing IL-6 levels in a patient comprising administering locally a locally effective IL-6 increasing amount of bioactive glass particles with a size less than about 20 μm to the patient.
- 13. The method of claim 12 wherein the locally effective IL-6 increasing amount of bioactive glass particles is administered by intraperitoneal injection.
- 14. The method of claim 13 wherein the locally effective IL-6 increasing amount of bioactive glass particles is administered prophylactically or therapeutically to prevent or treat peritoneal adhesions.
- 15. The method of claim 13 wherein the locally effective IL-6 increasing amount of bioactive glass particles is administered by peritoneal injection of a composition comprising the bioactive glass particles, a suitable carrier for intraperitoneal injection, and one or more therapeutic agents.
- 16. The method of claim 15 wherein the one or more therapeutic agents are selected from the group consisting of healing promotion agents, growth factors, anti-inflammatory agents, and anesthetics.
- 17. The method of claim 13 wherein the bioactive glass particles have a size less than about 2 microns.
- 18. The method of claim 12 wherein the locally effective IL-6 increasing amount of bioactive glass particles is administered by inhalation.
- 19. The method of claim 12 wherein the locally effective IL-6 increasing amount of bioactive glass particles is administered by subcutaneous injection.
- 20. The method of claim 19 wherein the locally effective IL-6 increasing amount of bioactive glass particles is mixed with a biocompatible hydrogel.
- 21. The method of claim 19 wherein the locally effective IL-6 increasing amount of bioactive glass particles is administered at a site at which surgery is to be performed.
- 22. The method of claim 21 wherein the locally effective IL-6 increasing amount of bioactive glass particles is mixed with an anesthetic.
Parent Case Info
[0001] This application is a divisional application of U.S. application Ser. No. 09/560,475, filed Apr. 28, 2000, which claims the priority benefit of U.S. Provisional Application No. 60/131,529, filed Apr. 29, 1999. The entire content of U.S. application Ser. No. 09/560,475 and U.S. Provisional Application No. 60/131,529 are hereby incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60131529 |
Apr 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09560475 |
Apr 2000 |
US |
Child |
10703654 |
Nov 2003 |
US |